Helus Pharma (NASDAQ: HELP) (Cboe CA: HELP), a clinical-stage pharmaceutical company focused on developing novel serotonergic agonists (NSAs), has announced significant progress in its late-stage pipeline. The company reported that enrollment in its APPROACH Phase 3 pivotal study evaluating HLP003 for major depressive disorder (MDD) is now complete, with topline data expected in the fourth quarter of 2026. This milestone brings the company closer to potentially delivering a new treatment option for patients with MDD who have not responded adequately to existing therapies.
The APPROACH study is part of the PARADIGM program, which also includes the EMBRACE study, a second pivotal trial where enrollment is currently underway. Additionally, participants who complete these studies are rolling over into the EXTEND long-term extension study, designed to gather additional safety and efficacy data over an extended period. The advancement of these trials is supported by the company's strong cash position of $166.4 million as of June 30, 2026, which is expected to fund operations and ongoing research and development efforts.
Beyond HLP003, Helus Pharma is also making strides in its pipeline for generalized anxiety disorder (GAD). Following positive Phase 2 results for HLP004, which demonstrated statistically significant and clinically meaningful improvements from baseline, the company is designing the next study, with completion expected by the end of the third quarter of 2026. This progress underscores the potential of NSAs to address a range of mental health conditions beyond depression, targeting a large unmet need.
Financially, the company reported a net loss of $47.8 million for the quarter ended June 30, 2026, compared with a net loss of $24.6 million in the same period of the previous year. The increase is primarily attributed to higher cash-based operating expenses, which totaled $37.5 million versus $23.9 million a year earlier, driven by the continued advancement of the Phase 3 trials for HLP003. These investments are critical as the company moves toward potential regulatory filings and commercialization.
Helus Pharma is also progressing its earlier-stage pipeline, including HLP005, with a viable development candidate anticipated in the second half of 2027. This diverse portfolio positions the company to potentially offer multiple novel treatments for mental health conditions, leveraging its proprietary NSAs that are designed to activate serotonin pathways and promote neuroplasticity.
The company's lead candidate, HLP003, has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration, highlighting its potential to offer significant improvement over existing therapies. With the completion of enrollment in APPROACH and the ongoing EMBRACE study, the company is on track to deliver top-line data that could shape the future of MDD treatment. The positive Phase 2 results for HLP004 also signal potential for expansion into GAD, a condition affecting millions worldwide.
These developments are crucial for patients and investors alike, as they demonstrate tangible progress in addressing mental health challenges. The upcoming milestones, including the Q4 2026 topline data and the HLP004 study design, will be pivotal in determining the company's trajectory. With a robust financial position and a pipeline of innovative candidates, Helus Pharma is well-positioned to make a meaningful impact in the mental health landscape.
